As of mid-2026, VH-499 is moving forward in clinical development as a potential cornerstone of future ultra-long-acting treatment regimens. ViiV Healthcare continues to analyze PK (pharmacokinetic) and efficacy data to optimize dosing schedules for Phase 3 trials, aiming to solidify its role in both HIV treatment and potentially prevention (PrEP).
Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting. National AIDS Treatment Advocacy Project - NATAP
The most common adverse events were mild-to-moderate, short-lived injection site reactions, with no serious adverse events leading to study withdrawal. Advantages of VH-499